Wednesday, May 20, 2015

High Cost of Hepatitis C Drug Prompts a Call to Void Its Patents

High Cost of Hepatitis C Drug Prompts a Call to Void Its Patents
By ANDREW POLLACK
MAY 19, 2015
Activists in several countries are seeking to void patents on the blockbuster hepatitis C drug Sovaldi, saying that the price being sought by the manufacturer, Gilead Sciences, was prohibitive. 
The Initiative for Medicines, Access and Knowledge, a legal group in New York, is expected to announce Wednesday that it has filed challenges in Argentina, Brazil, China, Russia and Ukraine. In all those countries except China, the organization is being joined by local patient advocacy groups.
Continue reading....



No comments:

Post a Comment